What Is GLP-1 and Why Is Everyone Talking About It?

GLP-1 is a natural gut hormone. GLP-1 receptor agonists are the medications that mimic it — producing weight loss results and cardiovascular benefits that have genuinely surprised the medical world. Here is the complete plain-language explanation.

What is GLP-1? The science in plain language

GLP-1 stands for Glucagon-Like Peptide-1 — a hormone your body naturally produces in cells lining the small intestine in response to eating food. Think of GLP-1 as your body's natural signal that says food has been consumed and it is time to slow down and sort out the blood sugar. When you eat, GLP-1 is released and triggers several important responses: it stimulates insulin secretion from the pancreas but only when blood sugar is actually elevated, which is a key safety feature; it suppresses glucagon to prevent the liver from releasing excess glucose; it slows gastric emptying so food moves from the stomach more slowly, smoothing out the post-meal blood sugar spike; and it reduces appetite by acting on GLP-1 receptors in the brain's hunger-regulating centres. In type 2 diabetes and obesity, this GLP-1 system is impaired — insulin response is blunted, appetite regulation is dysregulated, and blood sugar control deteriorates.

From natural hormone to blockbuster drug

The clinical breakthrough was straightforward in concept but took decades to achieve in practice: what if you could give people a version of GLP-1 that lasted much longer than the natural hormone, which breaks down within minutes, and was far more potent? Starting with liraglutide and culminating in semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro), researchers created GLP-1 receptor agonists — molecules that mimic GLP-1 but are modified to last up to seven days in the bloodstream, enabling once-weekly injection. Mounjaro (tirzepatide) goes a step further by activating a second hormonal pathway called GIP alongside GLP-1, producing even greater metabolic effects. For a full comparison of Mounjaro and Ozempic: Mounjaro vs Ozempic — which weight loss treatment is better?.

Why GLP-1 transformed diabetes treatment

Managing type 2 diabetes with older medications — metformin, sulphonylureas, insulin — primarily focused on lowering blood sugar. But sulphonylureas and insulin cause weight gain, worsening the underlying metabolic disease, and they cause hypoglycaemia, a significant risk especially in elderly patients. GLP-1 receptor agonists changed this entirely: they lower blood sugar without causing weight gain, they have a glucose-dependent mechanism that does not cause hypoglycaemia when used alone, and they address multiple metabolic pathways simultaneously across the liver, pancreas, brain, gut, and fat tissue. For people with type 2 diabetes in Srinagar, this represents a fundamentally different approach to management. Monitor your response with regular HbA1c testing at home and see our guide on managing diabetes at home in Kashmir.

Why GLP-1 transformed obesity treatment

Obesity is a chronic neurobiological disease in which the brain's regulation of appetite, food reward, and energy balance is fundamentally altered. GLP-1 receptor agonists act directly on the brain centres controlling appetite and food reward — correcting an underlying hormonal dysregulation rather than simply suppressing appetite with stimulants. The clinical trial results were unlike anything medicine had previously achieved without surgery. The STEP 1 trial with semaglutide produced average weight loss of 14.9% of body weight. The SURMOUNT-1 trial with tirzepatide (Mounjaro) produced average weight loss of 20.9% of body weight. Many patients report that food becomes less central to their daily experience, cravings diminish, and eating becomes less emotionally driven. Maintaining adequate protein intake and physical activity during treatment is important — physiotherapy services in Srinagar can support patients in building and preserving muscle during weight loss.

The cardiovascular breakthrough: the SELECT trial

Perhaps the most significant development in GLP-1 research beyond weight loss is the cardiovascular outcomes data. The SELECT trial published in the New England Journal of Medicine in 2023 involved over 17,000 adults with obesity and established cardiovascular disease. Semaglutide reduced the risk of major cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% compared to placebo. This is the first and only obesity medication to demonstrate such significant cardiovascular mortality benefit. The finding matters especially for residents of Srinagar and Kashmir, where cardiovascular disease rates are elevated. For context on cardiovascular risk assessment alongside GLP-1 treatment, see our guide on cardiac screening in Srinagar and consider testing your Lp(a) and ApoB as baseline cardiac markers before starting treatment.

Blood test monitoring during GLP-1 treatment

People using GLP-1 medications should undergo regular blood test monitoring throughout their treatment. HbA1c should be checked every three months initially, then every six months, to monitor blood sugar response. Kidney function should be checked every six months given dehydration risk from gastrointestinal side effects. Liver function at baseline and annually. A lipid panel every six to twelve months to track metabolic improvements. All of these tests are available through home sample collection in Srinagar — there is no need to visit a hospital or lab for ongoing monitoring. For elderly patients or those with mobility limitations, elderly care services and home nursing can support ongoing monitoring at home. To discuss GLP-1 treatment options with a physician without leaving your home, book a doctor home visit in Srinagar.